Join us in the Washington, D.C. office of Reed Smith LLP for an engaging and interactive program discussing the implementation and commercialization in healthcare 3D printing and bioprinting applications, and the barriers associated with making this leap!
When: February 27, 2019. 6:30pm-9:30pm
6:30-7:00 PM Registration/Networking
7:00-7:15 PM ReedSmith LLP sponsor intro (Matthew Jacobson) /3DHEALS community manager Ben Holmes intro
7:15-7:25 PM Ben Holmes (Nanochon)
7:25-7: 30 PM Q&A
7:30-7: 40 PM Jeff Vockrodt (Arent Fox)
7:40-7:45 PM Q&A
7:45-7:55 PM Jon Rowley (RoosterBio) :
7:55-8:00 PM Q&A
8:00-8:10 PM Yi Arnold (Theradaptive) :Targeted Therapeutics Delivery for Tissue Regeneration.
8:10-8:15 PM Q&A
8:15-8:45 PM Panel Q&A
8:45-9:30 PM Networking and wrap-up
(After event location will be announced to continue the conversations.)
Dr. Holmes received his Ph.D. at the George Washington University, where his work focused on new materials and 3-D printing for stem cell growth and tissue repair. Dr. Holmes has been awarded several patents, published numerous journal articles, and contributed a chapter to the book Tissue and Organ Regeneration: Advances in Micro- and Nanotechnology (Pan Stanford Publishing, 2014). In addition to research, he has a strong record in entrepreneurship. Receiving training from the National Science Foundation’s I-Corps program and VentrueWell’s ASPIRE program for medical device companies, Dr. Holmes has been the Vice President for Technology at medical device company SonoStik since 2013 and founded his own company Nanochon in 2016. He has demonstrated a strong early-stage funding track record, bringing Nanochon various grants, a Phase I SBIR award from the NSF and seed stage investment. See our interview with Ben last year.
Matt Jacobson is counsel in Reed Smith LLP’s Life Sciences Health Industry Group and a member of the firm’s 3D Printing taskforce. He focuses his practice primarily on product liability litigation for medical device companies. Matt has an interest in how 3D printing is changing how products are designed, developed, manufactured, and distributed, and in what way these changes affect product liability laws. He has been described as one of the authorities in this area and is a thought leader writing and presenting numerous times on the topic. Matt also helps advise clients to manage exposure and risk and reduce uncertainty as this novel technology changes the product liability landscape. Matt can be reached at [email protected]
Jeff Vockrodt advises companies on patent matters involving chemical and life science technologies, including pharmaceutical, medical device, and biotechnology inventions. Jeff has overseen the preparation and prosecution of hundreds of patent applications involving a wide range of technologies, including additive manufacturing and biopharmaceutical patents. Jeff has served as lead counsel in inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB). Jeff is a registered patent attorney with a chemical engineering background. He served for four years as patent examiner before the United States Patent and Trademark Office and a law clerk in the US International Trade Commission before entering private practice. He is currently a partner at Arent Fox LLP and adjunct professor teaching IP, Regulation & Compliance for Biotechnology at Katz Business School, Yeshiva University. See our interview with Jeff last year.
Jon A. Rowley, Ph.D., is the Founder & Chief Product Officer of RoosterBio Inc. Jon started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Jon holds a Ph.D. from the University of Michigan in Biomedical Engineering and has authored over 35 peer-reviewed manuscripts and 20 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Jon started his industry career at BD as a scientist and R&D manager in a Cell & Tissue Technologies group focused on applying high throughput screening technologies to cell therapy media development and tissue engineering. Jon then contributed to the clinical development of Aastrom Biosciences’ Tissue Repair Cell product, where he was Sr Manager of Process Development responsible for manufacturing process improvements and cell delivery to the patient. Jon most recently spent 5 years as Director of Innovation and Process Development in Lonza’s Cell Therapy CMO business, and currently resides in Walkersville, MD with his wonderful wife and their three children.
Yi Arnold, Ph.D.
Yi Arnold, Ph.D. is the Director of Business Development and R&D of Theradaptive. Theradaptive is a regenerative medicine startup that has developed a platform for targeted delivery of potent regenerative therapeutics for tissue regeneration. Theradaptive is combining the latest 3D printing technology with its biologic delivery platform to design implants mimicking the native ECM for better and faster tissue repair and regeneration. Current programs include long bone repair, spine fusion, dental & CMF repair, and osteochondral repair. Prior to Theradaptive, Yi was a VP at Esco Venture, a Singapore-based Venture Capital group and a Director at Osiris Therapeutics, managing their wound care portfolio. Yi started her industry career at Kinetic Concepts, Inc. and has since developed and brought to market 3 human tissue-based products for wound repair, estimated at over $100 million yearly revenue. Yi holds a BS in Mechanical Engineering, a Ph.D. in Biomedical Engineering and received her postdoc training at Yale and Columbia University. Yi currently resides in Ellicott City, MD with her husband and two girls. She loves to run marathons in her spare time and is excited to be running the BMW Berlin Marathon in 2019!
Thanks to our sponsor Reed Smith LLP for venue and refreshments!